Lannett Banks On Pipeline As Competition Bites
US Firm Emphasizes Promise Of Future Launches Amid ‘Ongoing’ Pressures And Returns
Executive Summary
Lannett once again saw its sales and profits hit by “ongoing competitive pressures” as well as a high rate of product returns in its financial third quarter. However, the company is banking on several major long-term pipeline opportunities, as well as a handful of nearer-term launches, to reverse its decline.
You may also be interested in...
Tough Q1 In US For Glenmark, Eyes on Ryaltris Debut, Flovent Rival Filing
Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.
Tough Q1 In US For Glenmark, Eyes on Ryaltris Debut, Flovent Rival Filing
Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.
Can The Pipeline Soothe A US Generics Pricing Headache?
Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.